Article Text

Download PDFPDF
Select wisely: the ethical challenge of defining large core with perfusion in the early time window

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @ashupjadhav, @clauszsimonsen, @Fie0815

  • Contributors All authors contributed to the drafting and final approval of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests WH reports consultancy fees from Neuravi and fees for DSMB work by Phenox. DWJD reports funding from the Dutch Heart Foundation, Brain Foundation Netherlands, The Netherlands Organisation for Health Research and Development, Health Holland Top Sector Life Sciences & Health, and unrestricted grants from Penumbra, Stryker European Operations BV, Medtronic, Thrombolytic Science, LLC and Cerenovus for research, all paid to institution. CZS reports research grants from Novo Nordisk Foundation and Health Research Foundation of Central Denmark Region. JF reports research support from the German Ministry of Science and Education (BMBF and BMWi), German Research Foundation (DFG), European Union (EU), Hamburgische Investitions- und Förderbank (IFB), Medtronic, Microvention, Philips, Stryker, and consultancy fees from Acandis, Boehringer Ingelheim, Cerenovus, Covidien, Evasc Neurovascular, MD Clinicals, Medtronic, Medina, Microvention, Penumbra, Route92, Stryker, Transverse Medical. GT reports personal fees from Acandis, grants and personal fees from Bayer, personal fees from Boehringer Ingelheim, personal fees from Bristol-Myers-Squibb/Pfizer, personal fees from Portola, and personal fees from Stryker outside the submitted work, and is Neurological Co-Principal Investigator of the TENSION study, which receives funding from the European Union’s Horizon 2020 research and innovation program under grant agreement number 754640. TA reports consultancy fees from Amnis Therapeutics, Anaconda, Cerenovus/Neuravi, Rapid Medical and Stryker. MM is a member of the TESLA steering committee and local principal investigator. He reports research support from the NIH and consultancy fees from Medtronic and Cerenovus as well as stock options in Serenity Medical, Synchron and Endostream. AJY is the co-Principal Investigator for TESLA and reports research funding from Medtronic, Cerenovus, Penumbra and Stryker. He reports consultancy fees from Penumbra, Cerenovus, Vesalio and Zoll Circulation. He has equity interests in Insera Therapeutics. SAS reports research support from the NIH, American Academy of Neurology and Society for Vascular and Interventional Neurology, and consultancy fees from Penumbra and Cerenovus. OOZ is the co-Principal Investigator for TESLA and reports consultancy fees from Cerenovus, Stryker, Penumbra and Medtronic. TGJ reports consultancy fees from Cerenovus and Contego, and research support from Stryker. DL reports consultancy fees from Cerenovus, Genentech, Medtronic, and Stryker outside the submitted work.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • Commentary
    Amrou Sarraj Bruce Campbell Marc Ribo Muhammad Shazam Hussain Michael Chen Michael G Abraham Maarten G Lansberg Vitor Mendes Pereira Spiros Blackburn Clark W Sitton Ronald F Budzik Natalia Pérez de la Ossa Juan F Arenillas Teddy Wu Jordi Blasco Michael Mullen Joanna Schaafsma Jenny P Tsai Navdeep Sangha Osman Kozak Daniel Gibson Steven Warach Dennis Cordato Nathan W Manning Timothy J Kleinig Jean-Marc Olivot Lucas Elijovich Georgios Tsivgoulis Andrei Alexandrov Pascal Jabbour Bernard Yan Scott E Kasner Adam S Arthur Mark Parsons James C Grotta Ameer E Hassan Gregory W Albers
  • Commentary
    Zeguang Ren Xiaochuan Huo Gaoting Ma Xu Tong Jay Kumar Elliot Pressman Wenhuo Chen Guangxiong Yuan Alvin Yi-Chou Wang Ming Wei Jiangang Zhang Guangxian Nan Qiyi Zhu Yajie Liu Liyong Zhang Weigen Song Zhiming Zhou Guoqing Wang Tianxiao Li Jun Luo En Wang Wentong Ling Dongsheng Ju Cunfeng Song Shu-Dong Liu Liqiang Gui Tong Li Yan Liu Junfeng Zhao Zaiyu Guo Hongbo Zheng Yaxuan Sun Na Xu Yong Jun Wang Zhongrong Miao on behalf of ANGEL-ASPECT Investigators and ANGEL-ASPECT Steering Committee Miao Zhongrong Ren Zeguang Vitor Mendes Pereira Huo Xiaochuan Ma Gaoting; Tong Xu Zhang Xuelei Sun Dapeng Liu Zhenqiang Yang Ming Zhang Yupeng Nie Ximing Wei Na Yang Bo Meng Xia Pan Yuesong Wang Anxin Liu Liping Wang Yilong Wang Yongjun Ji Xunming Liu Xinfeng Dong Qiang Xu Anding Yang Qingwu Geng Xiaokun Zhang Shiyong Zhou Zhiming Chen Wenhuo Wang Yizhou Liao Geng Liu Yajie Ling Wentong LI Tong; Xu Guodong Gui Liqiang Li Tianxiao; Zhang Jiangang Ju Dongsheng Zhao Junfeng Shi Haibin Pen Ya Liu Yan Shi Hongchao Wu Jin Ding Yasuo Song Weigen Li Di; Jiang Changchun Zhu Qiyi Han Hongxing Wang Guoqing Song Cunfeng LI Weirong; Zhao Jing Bi Yong Zheng Hongbo Luo Jun Li Jinglun; Wei Ming Guo Zaiyu Yin Congguo Wang En Liu Shudong Cai Chuwei Zhang Meng Cai Xueli Nan Guangxian Zhang Liyong Yang Hua Sun Yaxuan Xu Na Yang Xinguang Yuan Guangxiong Dai Linzhi Huang Wenguo Gao Zongen Shi Qing Tang Yufeng Yue Wencan Wen Changming Miao Zhongrong Ren Zeguang Vitor Mendes Pereira Wang Yongjun Wang Yilong Liu Liping David Liebeskind